### Abbott Laboratories (ABT) Overview
**Company Information:**
- **Name:** Abbott Laboratories
- **Ticker:** ABT
- **Industry:** Health Care Equipment & Supplies
- **Market Cap:** $189.14 Billion
- **P/E Ratio:** 34.29
- **IPO Date:** March 1, 1937
- **Employees:** 114,000
- **Headquarters:** Abbott Park, Illinois, USA
- **Website:** [Abbott Laboratories](https://www.abbott.com)
- **Investor Relations:** [Investor Relations](https://www.abbott.com/investors.html)
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. The company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
**Latest Price Information:**
- **Last Close Price:** $108.71 (August 9, 2024)
- **Opening Price:** $109.28
- **Current After-Hours Price:** $108.52
- **Price Change:** -0.52% from opening to close
**Technical Analysis:**
- **Trend:** Bullish
- **Indicators:**
- Price above 20-day and 40-day EMAs
- Widening Bollinger Bands indicating increased volatility
- MACD above the signal line suggesting bullish momentum
- RSI above 50 indicating strength in the current trend
- **Analyst Recommendations:** Majority rate as 'strong buy' or 'buy'
- **Entry Signal:** $112.00
- **Exit Signal:** $120.00
**Latest Quarterly Financials (Q2 2024):**
- **Net Sales:** $10.377 Billion (up from $9.978 Billion in Q2 2023)
- **Operating Earnings:** $1.669 Billion (up from $1.542 Billion in Q2 2023)
- **Net Earnings:** $1.302 Billion (down from $1.375 Billion in Q2 2023)
- **Basic EPS:** $0.74 (down from $0.79 in Q2 2023)
- **Diluted EPS:** $0.74 (down from $0.78 in Q2 2023)
**Recent News:**
1. **Myriad Genetics Q2 2024 Earnings**: Myriad Genetics reported strong earnings, with notable performance in hereditary cancer and pharmacogenomics testing. Abbott Laboratories is mentioned as a notable stock with a Zacks Rank #2. [Read more](https://finnhub.io/api/news?id=9257fe4961b248529c392c45a497abb44b9296320650a2271a595a1a2755d670)
2. **Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors**: Abbott is highlighted for its strong dividend performance, financial growth, and solid balance sheet. The stock is considered attractive for long-term growth. [Read more](https://finnhub.io/api/news?id=09406129d3f3c204fbf3ed930bc9d49e1c99af496759f214330cd91e3347618e)
3. **Globus Medical Q2 2024 Earnings**: Globus Medical reported strong earnings, with Abbott Laboratories mentioned as a notable stock with a Zacks Rank #2. [Read more](https://finnhub.io/api/news?id=670e1d5d7e65cf79a04887678aeb529c2c40ed0c69a0ee35af9131ce69e11925)
### Summary
Abbott Laboratories is a well-established healthcare company with a strong market presence and diverse product lines. The company has shown consistent financial performance and is considered a strong buy by analysts. Recent news highlights its strong dividend growth and solid financial health, making it an attractive option for long-term investors.
Would you like to see a price chart for Abbott Laboratories (ABT)?
Comments